Cellipont Bioservices is a cell therapy Contract Development and Manufacturing Organisation (CDMO) with over 15 years of experience in the development and manufacturing of cell therapies across a wide range of applications. The company is dedicated to helping clients expand patient access to life-changing medicines by providing best-in-class development, analytical, and manufacturing capabilities. With a robust portfolio consisting of more than 18,000 tissue samples and 1,800+ primary cell cultures, Cellipont has built a deep expertise in the field of cell and gene therapy.

Services include:
- Creation of master and working cell banks
- Analytical and process development
- Manufacturing services for preclinical (research & development) to Phase I-II

Cellipont Bioservices offers extensive experience across multiple product areas, including CAR-T, iNK, dendritic cell, and other novel cell therapy approaches. To learn more about Cellipont Bioservices and its extensive offerings, visit cellipont.com.